Robin Ray, MD
Ophthalmology · Savannah, GANPI 1306006226
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $5,461 of the $7,100 with a category attached, or 76.9%. US Retina LLC accounts for 76.9% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2022 at $2,711 and has fallen 86.6% since, to $364 in 2025.
Across 77 payments — averaging $92.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$5K
- Regeneron Healthcare Solutions, Inc.$809
- Genentech USA, Inc.$495
- Apellis Pharmaceuticals, Inc.$71
- Eyepoint US, Inc.$66
- Harrow Eye, LLC$56
- plus $141 from 6 others
What the payments were for
- Food & beverage$1,63823%
- Ownership interest$5,46177%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 6 | $5,461 |
| Regeneron Healthcare Solutions, Inc. | 29 | $809 |
| Genentech USA, Inc. | 24 | $495 |
| Apellis Pharmaceuticals, Inc. | 4 | $71 |
| Eyepoint US, Inc. | 4 | $66 |
| Harrow Eye, LLC | 3 | $56 |
| Novartis | 2 | $35 |
| AbbVie | 1 | $24 |
| Alimera Sciences, Inc. | 1 | $23 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Coherus Oncology, Inc. | 1 | $20 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
How this compares
$7,100 in reported general payments places this provider in the 80th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 221 | $9,212 |
| RestasisCyclosporine | 12 | $7,590 |
| Latanoprost | 220 | $1,913 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 84 | $1,130 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 83 | $951 |
| Diclofenac Sodium | 57 | $619 |
| Brimonidine Tartrate | 81 | $552 |
| Dorzolamide Hcl | 25 | $423 |
| Timolol Maleate | 70 | $411 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 43 | $338 |
| Prednisone | 29 | $126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $24 | $7,59012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Savannah
- Markesh ManochaSavannah$63K
- Thomas KandlSavannah$26K
- Gagan SawhneyAtlanta$582K
- Lawrence WoodardAtlanta$578K
- Stephanie VanderveldtAtlanta$384K
- Steven YehAtlanta$289K
- Jack ChapmanGainesville$244K
- Gregory LeeCumming$214K
- Puneet PandaMarietta$185K
- Jeffrey TranSuwanee$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.